Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.
Anca Chelariu-RaicuSarina A Piha-PaulMariana Chavez-MacGregorJason JohnsonRaymond SawayaMary Frances McAleerAlissa NguyenAudrey HartnettApostolia M TsimberidouFunda Meric-BernstamEcaterina E DumbravaPublished in: Journal of immunotherapy and precision oncology (2023)
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except for BRCA1/2 mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.
Keyphrases
- epidermal growth factor receptor
- case report
- positive breast cancer
- metastatic breast cancer
- brain metastases
- palliative care
- resting state
- small cell lung cancer
- quality improvement
- tyrosine kinase
- white matter
- dna repair
- endothelial cells
- advanced non small cell lung cancer
- early onset
- healthcare
- functional connectivity
- dna damage
- breast cancer risk
- cerebral ischemia
- brain injury
- induced pluripotent stem cells
- pain management
- chronic pain
- oxidative stress
- blood brain barrier
- mass spectrometry
- subarachnoid hemorrhage